Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies

Cancer Science
Daigo AkahaneKazuma Ohyashiki

Abstract

Despite promising results from clinical studies of ABL kinase inhibitors, a challenging problem that remains is the T315I mutation against which neither nilotinib nor dasatinib show significant activity. In the present study, we investigated the activity of a novel Aurora kinase inhibitor, VE-465, against leukemia cells expressing wild-type BCR-ABL or the T315I mutant form of BCR-ABL. We observed a dose-dependent reduction in the level of BCR-ABL autophosphorylation in VE-465-treated cells. Exposure to the combination of VE-465 and imatinib exerted an enhanced apoptotic effect in K562 cells. Combined treatment with VE-465 and imatinib caused more attenuation of the levels of phospho-AKT and c-Myc in K562 cells. Further, the isobologram indicated the synergistic effect of simultaneous exposure to VE-465 and imatinib in K562 cells. To assess the in vivo efficacy of VE-465, athymic nude mice were injected intravenously with BaF3 cells expressing wild-type BCR-ABL or the T315I mutant form. The vehicle-treated mice died of a condition resembling acute leukemia by 28 days; however, nearly all mice treated with VE-465 (75 mg/kg, twice daily; intraperitoneally for 14 days) survived for more than 56 days. Histopathological analysis of v...Continue Reading

References

Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Aug 1, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sergei RoumiantsevRichard A Van Etten
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group
Mar 20, 2004·Science·Martin E M NobleLouise N Johnson
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Dec 2, 2004·Nature Reviews. Drug Discovery·Henrik DaubAxel Ullrich
Feb 16, 2005·Cancer Cell·Ellen WeisbergJames D Griffin
Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Jul 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Todd A CarterDavid J Lockhart
Jun 8, 2006·International Journal of Hematology·Tetsuzo Tauchi, Kazuma Ohyashiki
Jul 5, 2006·Cancer Research·Ajoy K SamantaRalph B Arlinghaus
Nov 23, 2006·Biochemical and Biophysical Research Communications·Chongbo SunSpiros Linardopoulos

❮ Previous
Next ❯

Citations

Jul 2, 2009·Nature Reviews. Drug Discovery·Silvia Lapenna, Antonio Giordano
Jun 14, 2012·Pathology International·Shin-ichiro KiyoseHaruhiko Sugimura
Dec 17, 2008·Journal of Translational Medicine·Christopher D ScharerCarlos S Moreno
May 11, 2011·Expert Opinion on Drug Discovery·Myke R GreenDaruka Mahadevan
Mar 1, 2011·Expert Opinion on Emerging Drugs·Aine Carol BurkeFrancis J Giles
Sep 25, 2010·Biochimica Et Biophysica Acta·Hiroshi Katayama, Subrata Sen
Mar 5, 2016·Journal of Cancer Research and Clinical Oncology·Jonas Cicenas
Feb 24, 2009·Experimental Cell Research·Megan R DreierWilliam R Taylor
Aug 29, 2009·Medicinal Research Reviews·S SchenoneM Botta
Oct 8, 2013·PLoS Pathogens·Sebastian HannemannJorge E Galán
Nov 22, 2013·PloS One·Sónia Troeira HenriquesDavid J Craik
Oct 19, 2013·Seminars in Oncology·Panisinee LawasutConstantine S Mitsiades
Apr 29, 2010·Current Hematologic Malignancy Reports·Meetu AgrawalAlfonso Quintás-Cardama
May 15, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Iker López-CaldereroRocío García-Carbonero
Jul 20, 2010·Current Oncology Reports·Meetu AgrawalJorge Cortes
Jul 15, 2018·Clinical and Experimental Medicine·Carla de Castro Sant' AnnaRommel Rodriguez Burbano
Mar 27, 2009·Journal of Medicinal Chemistry·John R Pollard, Michael Mortimore

❮ Previous
Next ❯

Related Concepts